Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rhythm Biosciences Ltd. ( (AU:RHY) ) has issued an announcement.
Rhythm Biosciences Ltd has announced the publication of a peer-reviewed study in PLoS One, detailing an enhanced colorectal cancer risk assessment model. This new model, an extension of the geneType™ product line, incorporates sex-specific and additional risk factors, outperforming existing models. The study, which used data from nearly 400,000 individuals in the UK Biobank, highlights the model’s superior predictive ability and its potential for commercial clinical applications. The innovation underscores Rhythm’s commitment to advancing cancer risk prediction and improving stratified screening, positioning the company as a leader in predictive diagnostics technology.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd (ASX: RHY) is an Australian medical diagnostics company focused on developing simple, affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes by detecting cancers at the earliest stages, thereby reducing the global cancer burden. Rhythm Biosciences collaborates with global partners to commercialize and distribute their solutions, including the ColoSTAT® Test-Kit for colorectal cancer detection.
Average Trading Volume: 222,159
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$18.29M
See more insights into RHY stock on TipRanks’ Stock Analysis page.